Artemis Wealth Advisors LLC Has $1.78 Million Stock Holdings in Johnson & Johnson $JNJ

Key Points

• Artemis Wealth Advisors increased its Johnson & Johnson stake by 205.1% in the second quarter, acquiring 4,706 additional shares for a total of 7,000 shares valued at approximately $1.78 million. Institutional investors collectively own 69.55% of J&J.
• Johnson & Johnson reported quarterly EPS of $2.90 and revenue of $25.31 billion, exceeding analyst expectations, while revenue rose 6.6% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $268.22.
• The company declared a quarterly dividend of $1.34 per share, equivalent to an annualized $5.36 and a 2.0% yield. However, insiders sold 63,972 shares worth roughly $16.25 million over the past 90 days.

Artemis Wealth Advisors LLC lifted its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 205.1% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 7,000 shares of the company's stock after acquiring an additional 4,706 shares during the quarter. Artemis Wealth Advisors LLC's holdings in Johnson & Johnson were worth $1,778,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Blueline Advisors LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $25,000. Cresta Advisors Ltd. acquired a new position in Johnson & Johnson during the fourth quarter worth approximately $26,000. Bay Harbor Wealth Management LLC raised its stake in Johnson & Johnson by 49.0% in the fourth quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company's stock valued at $31,000 after buying an additional 49 shares during the period. Semmax Financial Advisors Inc. lifted its position in shares of Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company's stock valued at $31,000 after buying an additional 72 shares during the last quarter. Finally, E Fund Management Hong Kong Co. Ltd. lifted its position in shares of Johnson & Johnson by 946.7% in the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 157 shares of the company's stock valued at $32,000 after buying an additional 142 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

Several brokerages have issued reports on JNJ. HSBC set a $290.00 price target on Johnson & Johnson and gave the company a "buy" rating in a report on Monday, July 6th. Argus set a $300.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, July 29th. Royal Bank Of Canada lifted their target price on shares of Johnson & Johnson from $265.00 to $287.00 and gave the stock an "outperform" rating in a report on Monday, July 13th. Citigroup upped their price target on shares of Johnson & Johnson from $285.00 to $298.00 and gave the company a "buy" rating in a research note on Wednesday, July 8th. Finally, The Goldman Sachs Group restated a "buy" rating and set a $282.00 price objective on shares of Johnson & Johnson in a research report on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and an average price target of $268.22.

Johnson & Johnson Stock Up 0.1%

NYSE JNJ opened at $268.30 on Monday. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The company has a market cap of $646.58 billion, a price-to-earnings ratio of 31.09, a PEG ratio of 2.56 and a beta of 0.24. The company has a 50 day moving average of $258.88 and a 200-day moving average of $243.98. Johnson & Johnson has a 1-year low of $173.33 and a 1-year high of $276.47.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.84 by $0.06. The business had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The firm's quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities research analysts expect that Johnson & Johnson will post 11.61 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson's dividend payout ratio is presently 62.11%.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: China approved J&J’s oral psoriasis pill, Icotyde, expanding the company’s immunology portfolio and giving it a simpler treatment option to compete with rival products from Bristol Myers Squibb and AbbVie. The pill could also broaden J&J’s presence in China, although it may compete with the company’s established injectable Tremfya franchise. China approves J&J's oral psoriasis pill
• Positive Sentiment: The FDA expanded approval of Imaavy for warm autoimmune hemolytic anemia in patients 12 and older who are receiving or have previously received steroids. As the first approved treatment for this rare, potentially life-threatening disorder, Imaavy addresses an unmet need and could support J&J’s rare-disease growth strategy. Imaavy expands into rare blood disorder
• Positive Sentiment: Recent analysis points to a favorable shift in J&J’s product mix, with newer products increasingly offsetting pressure from the STELARA patent loss. This supports the view that growth in the broader Innovative Medicine portfolio may be more important than the shrinking contribution from STELARA. Did a product swap fuel JNJ stock's surge?
• Positive Sentiment: Investors continue to view JNJ as a defensive dividend holding, supported by its balance sheet, diversified healthcare operations and ability to generate dependable returns through economic cycles. Johnson & Johnson is a top dividend stock

Insider Activity

In other news, EVP Elizabeth Forminard sold 15,918 shares of the business's stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the completion of the transaction, the executive vice president directly owned 16,994 shares in the company, valued at approximately $4,367,458. The trade was a 48.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Vanessa Broadhurst sold 23,054 shares of the firm's stock in a transaction on Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the sale, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,779,963.81. This represents a 50.06% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 63,972 shares of company stock valued at $16,245,605 in the last 90 days. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source